Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Subscribe To Our Newsletter & Stay Updated